FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386119836> ?p ?o ?g. }

• W4386119836 abstract "Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies with a low 5-year survival rate and high rate of relapse. Developing more efficient therapies is an urgent need for AML treatment. Accumulating evidence showed that ferroptosis, an iron-dependent form of programmed cell death, is closely correlated with cancer initiation and clinical outcome through reshaping the tumor microenvironment. However, understanding of AML heterogeneity based on extensive profiling of ferroptosis signatures remains to be investigated yet. Herein, five independent AML transcriptomic datasets (TCGA-AML, GSE37642, GSE12417, GSE10358, and GSE106291) were obtained from the GEO and TCGA databases. Then, we identified two ferroptosis-related molecular subtypes (C1 and C2) with distinct prognosis and tumor immune microenvironment (TIME) by consensus clustering. Patients in the C1 subtype were associated with favorable clinical outcomes and increased cytotoxic immune cell infiltration, including CD8+/central memory T cells, natural killer (NK) cells, and non-regulatory CD4+ T cells while showing decreased suppressive immune subsets such as M2 macrophages, neutrophils, and monocytes. Functional enrichment analysis of differentially expressed genes (DEGs) implied that cell activation involved in immune response, leukocyte cell-cell adhesion and migration, and cytokine production were the main biological processes. Phagosome, antigen processing and presentation, cytokine-cytokine receptor interaction, B-cell receptor, and chemokine were identified as the major pathways. To seize the distinct landscape in C1 vs. C2 subtypes, a 5-gene prognostic signature (LSP1, IL1R2, MPO, CRIP1, and SLC24A3) was developed using LASSO Cox stepwise regression analysis and further validated in independent AML cohorts. Patients were divided into high- and low-risk groups, and decreased survival rates were observed in high- vs. low-risk groups. The TIME between high- and low-risk groups has a similar scenery in C1 vs. C2 subtypes. Single-cell-level analysis verified that LSP1 and CRIP1 were upregulated in AML and exhausted CD8+ T cells. Dual targeting of these two markers might present a promising immunotherapeutic for AML. In addition, potential effective chemical drugs for AML were predicted. Thus, we concluded that molecular subtyping using ferroptosis signatures could characterize the TIME and provide implications for monitoring clinical outcomes and predicting novel therapies." @default.
• W4386119836 created "2023-08-25" @default.
• W4386119836 creator A5025555679 @default.
• W4386119836 creator A5061976160 @default.
• W4386119836 creator A5066005227 @default.
• W4386119836 creator A5069469021 @default.
• W4386119836 creator A5072555479 @default.
• W4386119836 date "2023-08-24" @default.
• W4386119836 modified "2023-09-29" @default.
• W4386119836 title "Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment" @default.
• W4386119836 cites W1573108393 @default.
• W4386119836 cites W1573519072 @default.
• W4386119836 cites W1985197354 @default.
• W4386119836 cites W1989654707 @default.
• W4386119836 cites W1997183854 @default.
• W4386119836 cites W2002490399 @default.
• W4386119836 cites W2019448438 @default.
• W4386119836 cites W2022881751 @default.
• W4386119836 cites W2029506882 @default.
• W4386119836 cites W2067107606 @default.
• W4386119836 cites W2071754840 @default.
• W4386119836 cites W2103912979 @default.
• W4386119836 cites W2114586150 @default.
• W4386119836 cites W2115462905 @default.
• W4386119836 cites W2118519201 @default.
• W4386119836 cites W2146512944 @default.
• W4386119836 cites W2163123363 @default.
• W4386119836 cites W2165201727 @default.
• W4386119836 cites W2169353806 @default.
• W4386119836 cites W2201518863 @default.
• W4386119836 cites W2362534374 @default.
• W4386119836 cites W2418562824 @default.
• W4386119836 cites W2488521558 @default.
• W4386119836 cites W2518357275 @default.
• W4386119836 cites W2529409645 @default.
• W4386119836 cites W2556198943 @default.
• W4386119836 cites W2556439379 @default.
• W4386119836 cites W2582670998 @default.
• W4386119836 cites W2585283489 @default.
• W4386119836 cites W2601868035 @default.
• W4386119836 cites W2762087180 @default.
• W4386119836 cites W2766910695 @default.
• W4386119836 cites W2786943354 @default.
• W4386119836 cites W2792367722 @default.
• W4386119836 cites W2806219344 @default.
• W4386119836 cites W2809314900 @default.
• W4386119836 cites W2937346106 @default.
• W4386119836 cites W2942610007 @default.
• W4386119836 cites W2943793201 @default.
• W4386119836 cites W2952001873 @default.
• W4386119836 cites W2954870123 @default.
• W4386119836 cites W2958488683 @default.
• W4386119836 cites W2959498392 @default.
• W4386119836 cites W2965443476 @default.
• W4386119836 cites W2966732164 @default.
• W4386119836 cites W2981200992 @default.
• W4386119836 cites W2991034912 @default.
• W4386119836 cites W2995082030 @default.
• W4386119836 cites W2999212986 @default.
• W4386119836 cites W3003960907 @default.
• W4386119836 cites W3013967177 @default.
• W4386119836 cites W3015020891 @default.
• W4386119836 cites W3027286012 @default.
• W4386119836 cites W3030244068 @default.
• W4386119836 cites W3035153279 @default.
• W4386119836 cites W3089471337 @default.
• W4386119836 cites W3092260100 @default.
• W4386119836 cites W3097024336 @default.
• W4386119836 cites W3103119004 @default.
• W4386119836 cites W3120795654 @default.
• W4386119836 cites W3122102409 @default.
• W4386119836 cites W3124284550 @default.
• W4386119836 cites W3127932807 @default.
• W4386119836 cites W3135333594 @default.
• W4386119836 cites W3139362939 @default.
• W4386119836 cites W3158129026 @default.
• W4386119836 cites W3158830287 @default.
• W4386119836 cites W3160562205 @default.
• W4386119836 cites W3162306949 @default.
• W4386119836 cites W3169967031 @default.
• W4386119836 cites W3175752499 @default.
• W4386119836 cites W3194543059 @default.
• W4386119836 cites W3207264949 @default.
• W4386119836 cites W3212255416 @default.
• W4386119836 cites W3212646492 @default.
• W4386119836 cites W4225365552 @default.
• W4386119836 cites W4286249436 @default.
• W4386119836 cites W4290547238 @default.
• W4386119836 cites W4291464747 @default.
• W4386119836 doi "https://doi.org/10.3389/fcell.2023.1207642" @default.
• W4386119836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37691822" @default.
• W4386119836 hasPublicationYear "2023" @default.
• W4386119836 type Work @default.
• W4386119836 citedByCount "0" @default.
• W4386119836 crossrefType "journal-article" @default.
• W4386119836 hasAuthorship W4386119836A5025555679 @default.
• W4386119836 hasAuthorship W4386119836A5061976160 @default.
• W4386119836 hasAuthorship W4386119836A5066005227 @default.
• W4386119836 hasAuthorship W4386119836A5069469021 @default.
• W4386119836 hasAuthorship W4386119836A5072555479 @default.

• next